View Future GrowthPark Ha Biological Technology 과거 순이익 실적과거 기준 점검 0/6Park Ha Biological Technology 의 수입은 연평균 -83.5%의 비율로 감소해 온 반면, Specialty Retail 산업은 연평균 3.6%의 비율로 감소했습니다. 매출은 연평균 10.4%의 비율로 증가해 왔습니다.핵심 정보-83.53%순이익 성장률-82.10%주당순이익(EPS) 성장률Specialty Retail 산업 성장률26.64%매출 성장률10.36%자기자본이익률-609.90%순이익률-965.00%최근 순이익 업데이트31 Oct 2025최근 과거 실적 업데이트Reported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).Reported Earnings • Aug 27First half 2025 earnings released: US$0.74 loss per share (vs US$0.002 profit in 1H 2024)First half 2025 results: US$0.74 loss per share (down from US$0.002 profit in 1H 2024). Revenue: US$1.24m (up 45% from 1H 2024). Net loss: US$19.8m (down US$19.9m from profit in 1H 2024).Reported Earnings • Feb 25Full year 2024 earnings released: EPS: US$0.019 (vs US$0.034 in FY 2023)Full year 2024 results: EPS: US$0.019 (down from US$0.034 in FY 2023). Revenue: US$2.38m (down 3.1% from FY 2023). Net income: US$478.6k (down 44% from FY 2023). Profit margin: 20% (down from 35% in FY 2023). The decrease in margin was primarily driven by higher expenses.모든 업데이트 보기Recent updatesReported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).New Risk • Feb 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 111% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Market cap is less than US$10m (US$4.91m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (US$2.8m revenue).공시 • Jan 29Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million.Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 21,875,000 Price\Range: $0.112 Discount Per Security: $0.008New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Market cap is less than US$10m (US$4.95m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (US$2.8m revenue).공시 • Sep 20Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering.Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,428,571 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 11,428,571공시 • Sep 19Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025, at 10:00 China Standard Time. Location: 901, building c phase 2, wuxi international life science innovation campus, 196 jinghui east road xinwu district, wuxi ChinaReported Earnings • Aug 27First half 2025 earnings released: US$0.74 loss per share (vs US$0.002 profit in 1H 2024)First half 2025 results: US$0.74 loss per share (down from US$0.002 profit in 1H 2024). Revenue: US$1.24m (up 45% from 1H 2024). Net loss: US$19.8m (down US$19.9m from profit in 1H 2024).분석 기사 • Jul 10Some Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) Shareholders Look For Exit As Shares Take 94% PoundingPark Ha Biological Technology Co., Ltd. ( NASDAQ:PHH ) shareholders that were waiting for something to happen have been...New Risk • Jul 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$78.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Revenue has declined by 3.1% over the past year. Minor Risks Profit margins are more than 30% lower than last year (20% net profit margin). Revenue is less than US$5m (US$2.4m revenue). Market cap is less than US$100m (US$78.9m market cap).Reported Earnings • Feb 25Full year 2024 earnings released: EPS: US$0.019 (vs US$0.034 in FY 2023)Full year 2024 results: EPS: US$0.019 (down from US$0.034 in FY 2023). Revenue: US$2.38m (down 3.1% from FY 2023). Net income: US$478.6k (down 44% from FY 2023). Profit margin: 20% (down from 35% in FY 2023). The decrease in margin was primarily driven by higher expenses.New Risk • Jan 12New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid.공시 • Jan 08Park Ha Biological Technology Co., Ltd. Announces Appointment of Da Yang as an Independent DirectorOn January 7, 2025, the Board approved the appointment of Da Yang (Mr. Yang) as an independent director of the Park Ha Biological Technology Co., Ltd., effective January 7, 2025. Mr. Yang does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K. The biography for Mr. Yang is set forth below: Mr. Yang, aged 37, is an independent director of the Company. Mr. Yang has had many years of experience in sales and marketing. Mr. Yang served as the market director in Beijing New Space Technology Co., Ltd. since January 2021. From June 2017 to June 2020, Mr. Yang was a senior marketing manager in Gome Insurance Brokers Limited. From October 2015 to August 2016, Mr. Yang was an assistant to the general manager in Dade Liangju Trading (Beijing) Co., Ltd. Mr. Yang obtained his college degree in music performance (music) from Capital Normal University in 2008. The Board has determined that Mr. Yang qualifies as an independent director under the rules of the Nasdaq Stock Market LLC. In connection with his appointment, Mr. Yang will be entitled to receive the Company’s standard compensation provided to independent directors, pursuant to the independent director agreement between Mr. Yang and the Company.공시 • Dec 27Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million.Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: $4 Discount Per Security: $0.28매출 및 비용 세부 내역Park Ha Biological Technology가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NasdaqCM:BYAH 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Oct 253-2426031 Jul 253-2224030 Apr 253-1922031 Jan 253-911031 Oct 24201031 Jul 24201030 Apr 24201031 Jan 24211031 Oct 23211031 Oct 22201031 Oct 211010양질의 수익: BYAH 은(는) 현재 수익성이 없습니다.이익 마진 증가: BYAH는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: BYAH은 수익성이 없으며 지난 5년 동안 손실이 연평균 83.5% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 BYAH의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: BYAH은 수익성이 없어 지난 해 수익 성장률을 Specialty Retail 업계(-1.1%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: BYAH는 현재 수익성이 없으므로 자본 수익률이 음수(-609.9%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YRetail 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/26 22:18종가2026/05/26 00:00수익2025/10/31연간 수익2025/10/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Park Ha Biological Technology Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).
Reported Earnings • Aug 27First half 2025 earnings released: US$0.74 loss per share (vs US$0.002 profit in 1H 2024)First half 2025 results: US$0.74 loss per share (down from US$0.002 profit in 1H 2024). Revenue: US$1.24m (up 45% from 1H 2024). Net loss: US$19.8m (down US$19.9m from profit in 1H 2024).
Reported Earnings • Feb 25Full year 2024 earnings released: EPS: US$0.019 (vs US$0.034 in FY 2023)Full year 2024 results: EPS: US$0.019 (down from US$0.034 in FY 2023). Revenue: US$2.38m (down 3.1% from FY 2023). Net income: US$478.6k (down 44% from FY 2023). Profit margin: 20% (down from 35% in FY 2023). The decrease in margin was primarily driven by higher expenses.
Reported Earnings • Mar 04Full year 2025 earnings released: US$41.38 loss per share (vs US$0.96 profit in FY 2024)Full year 2025 results: US$41.38 loss per share (down from US$0.96 profit in FY 2024). Revenue: US$2.52m (up 6.0% from FY 2024). Net loss: US$24.4m (down US$24.8m from profit in FY 2024).
New Risk • Feb 02New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 111% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Shareholders have been substantially diluted in the past year (111% increase in shares outstanding). Market cap is less than US$10m (US$4.91m market cap). Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Revenue is less than US$5m (US$2.8m revenue).
공시 • Jan 29Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million.Park Ha Biological Technology Co., Ltd. has completed a Composite Units Offering in the amount of $2.45 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 21,875,000 Price\Range: $0.112 Discount Per Security: $0.008
New Risk • Jan 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 89% per year over the past 5 years. Market cap is less than US$10m (US$4.95m market cap). Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (US$2.8m revenue).
공시 • Sep 20Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering.Park Ha Biological Technology Co., Ltd. has filed a Follow-on Equity Offering. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 11,428,571 Security Name: Warrants Security Type: Equity Warrant Securities Offered: 11,428,571
공시 • Sep 19Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025Park Ha Biological Technology Co., Ltd., Annual General Meeting, Oct 03, 2025, at 10:00 China Standard Time. Location: 901, building c phase 2, wuxi international life science innovation campus, 196 jinghui east road xinwu district, wuxi China
Reported Earnings • Aug 27First half 2025 earnings released: US$0.74 loss per share (vs US$0.002 profit in 1H 2024)First half 2025 results: US$0.74 loss per share (down from US$0.002 profit in 1H 2024). Revenue: US$1.24m (up 45% from 1H 2024). Net loss: US$19.8m (down US$19.9m from profit in 1H 2024).
분석 기사 • Jul 10Some Park Ha Biological Technology Co., Ltd. (NASDAQ:PHH) Shareholders Look For Exit As Shares Take 94% PoundingPark Ha Biological Technology Co., Ltd. ( NASDAQ:PHH ) shareholders that were waiting for something to happen have been...
New Risk • Jul 09New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: US$78.9m This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Revenue has declined by 3.1% over the past year. Minor Risks Profit margins are more than 30% lower than last year (20% net profit margin). Revenue is less than US$5m (US$2.4m revenue). Market cap is less than US$100m (US$78.9m market cap).
Reported Earnings • Feb 25Full year 2024 earnings released: EPS: US$0.019 (vs US$0.034 in FY 2023)Full year 2024 results: EPS: US$0.019 (down from US$0.034 in FY 2023). Revenue: US$2.38m (down 3.1% from FY 2023). Net income: US$478.6k (down 44% from FY 2023). Profit margin: 20% (down from 35% in FY 2023). The decrease in margin was primarily driven by higher expenses.
New Risk • Jan 12New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shares are highly illiquid.
공시 • Jan 08Park Ha Biological Technology Co., Ltd. Announces Appointment of Da Yang as an Independent DirectorOn January 7, 2025, the Board approved the appointment of Da Yang (Mr. Yang) as an independent director of the Park Ha Biological Technology Co., Ltd., effective January 7, 2025. Mr. Yang does not have a family relationship with any director or executive officer of the Company and has not been involved in any transaction with the Company during the past two years that would require disclosure under Item 404(a) of Regulation S-K. The biography for Mr. Yang is set forth below: Mr. Yang, aged 37, is an independent director of the Company. Mr. Yang has had many years of experience in sales and marketing. Mr. Yang served as the market director in Beijing New Space Technology Co., Ltd. since January 2021. From June 2017 to June 2020, Mr. Yang was a senior marketing manager in Gome Insurance Brokers Limited. From October 2015 to August 2016, Mr. Yang was an assistant to the general manager in Dade Liangju Trading (Beijing) Co., Ltd. Mr. Yang obtained his college degree in music performance (music) from Capital Normal University in 2008. The Board has determined that Mr. Yang qualifies as an independent director under the rules of the Nasdaq Stock Market LLC. In connection with his appointment, Mr. Yang will be entitled to receive the Company’s standard compensation provided to independent directors, pursuant to the independent director agreement between Mr. Yang and the Company.
공시 • Dec 27Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million.Park Ha Biological Technology Co., Ltd. has completed an IPO in the amount of $4.8 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 1,200,000 Price\Range: $4 Discount Per Security: $0.28